Form 4: Ionis Pharmaceuticals Director Joseph H. Wender Receives Stock Options and Restricted Stock Units

Director Joseph H. Wender received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Summary

• On July 1, 2024, Joseph H. Wender, a director of Ionis Pharmaceuticals, received stock options and restricted stock units (RSUs) as part of the company's non-employee director compensation policy.
• The stock options grant was for 10,111 shares with an exercise price of $47.11, vesting on the earlier of July 1, 2025, or the next annual meeting, and expiring on June 30, 2034.
• The RSU grant was for 4,079 units, each representing one share of Ionis common stock or its equivalent cash value, vesting on the earlier of July 1, 2025, or the next annual meeting, and will be delivered on the July 15th following the vesting date.
• The grants were adjusted to ensure that the director's annual equity compensation does not exceed $450,000 based on the aggregate grant date fair value.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.
• The adjustment of the grants to stay within the $450,000 limit demonstrates responsible compensation practices.

Industry Context

Equity compensation is a common practice for directors of publicly traded companies to align their interests with shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize equity-based compensation for their board members.
• The specific amounts and vesting schedules vary based on company size, performance, and individual contributions.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates